(Q40648999)

22 September 2017

title

Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas (English)

1 reference

22 September 2017

Mehmet Ali Deveci

3

0 references

author name string

Semra Paydas

series ordinal

1

1 reference

22 September 2017

Emine Kilic Bagir

series ordinal

2

1 reference

22 September 2017

Gulfiliz Gonlusen

series ordinal

4

1 reference

22 September 2017

publication date

15 July 2016

1 reference

22 September 2017

1 reference

22 September 2017

volume

33

1 reference

22 September 2017

issue

8

1 reference

22 September 2017

page(s)

93

1 reference

Immune modulation for cancer therapy

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Immune inhibitory receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Immunotherapy in Sarcoma: Future Horizons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

PD-L1 and Survival in Solid Tumors: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Programmed cell death ligand 1 expression in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Kaposi's sarcoma and its associated herpesvirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-016-0807-Z

Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27421997

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

II. Contribution to the Knowledge of Sarcoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27421997

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Expression of programmed death 1 is correlated with progression of osteosarcoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27421997

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12032-016-0807-Z

1 reference

Dimensions Publication ID

22 September 2017

1011084909

0 references

1 reference